Omeros (OMER) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Omeros (OMER) has outperformed Pacira BioSciences (PCRX) over the past year, gaining 335.5% versus a gain of 55.4%. Over five years, OMER leads with a +147.3% price change compared with -31.6% for PCRX. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.44 billion), about 1.0 times the size.
On valuation, Pacira BioSciences trades at a lower forward P/E (10.5x vs 16.1x for Omeros).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OMER | PCRX |
|---|---|---|
| Share price | $19.83 | $36.31 |
| Market cap | $1.44B | $1.45B |
| 1-day change | +3.71% | -0.22% |
| YTD return | +11.29% | +40.61% |
| 1-year return | +335.54% | +55.45% |
| 5-year return | +147.35% | -31.60% |
| P/E ratio (TTM) | 16.25 | 103.74 |
| Forward P/E | 16.12 | 10.50 |
| EPS (TTM) | $1.22 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $726.41M |
| Revenue growth (YoY) | — | +3.63% |
| Net income (latest FY) | — | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | — | 2.64% |
| Net margin | — | 0.97% |
| 52-week high | $21.24 | $36.46 |
| 52-week low | $4.06 | $18.80 |
| Distance from 52-week high | -6.64% | -0.41% |
| Analyst consensus | none | buy |
| Avg. price target upside | +38.68% | -17.08% |
| Average volume | 1.74M | 1.03M |
| Shares outstanding | 72.39M | 39.91M |
| Employees | 175 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed PCRX by 280.1 percentage points over the past year.
- Pacira BioSciences trades at a higher earnings multiple (103.7x vs 16.3x trailing P/E).
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
OMER vs PCRX FAQ
Which is bigger, Omeros or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.44B for Omeros (OMER).
Which stock has performed better over the past year, OMER or PCRX?
OMER returned +335.54% over the past 12 months, compared with +55.45% for PCRX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, OMER or PCRX?
OMER has the lower trailing P/E at 16.3, versus 103.7 for PCRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Omeros and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.